ATLANTA – (COMMERCIAL THREAD) – NextGen Healthcare, Inc. (Nasdaq: NXGN), a leading provider of ambulatory technology solutions, today announced that at today’s annual meeting, shareholders of NextGen Healthcare have approved :
The reincorporation of NextGen Healthcare in Delaware
Elimination of cumulative voting in the election of directors
The election of the nine directors of the Company who are candidates for the Board of Directors, consisting of Craig A. Barbarosh, George H. Bristol, Darnell Dent, Julie D. Klapstein, Jeffrey H. Margolis, Dr. Geraldine McGinty, Morris Panner, Dr Pamela Puryear and David Sides
The ratification of the appointment of the independent registered accounting firm
Amendment and restatement of the 2015 action plan of NextGen Healthcare
NextGen Healthcare has released the following statement:
The Board of Directors and management of NexGen Healthcare thank our shareholders for their support. We are delighted to welcome our new directors.
We appreciate the views that stakeholders have shared throughout this process. During our conversations, shareholders recognized the many strengths of the company, including NextGen Healthcare’s winning platform, its talented and dedicated employees, and the benefits our services and solutions provide to healthcare providers and consumers. consumers across the country. Like us, shareholders see opportunities to further accelerate growth and value creation, and we are committed to doing so. The Board of Directors and management look forward to continuing the dialogue with our shareholders over the next year.
With the Annual Meeting behind us, we now turn our full attention to the business. The success of our customers is the key to ours. Our goal remains to provide innovative and comprehensive solutions that allow providers to engage with patients more effectively and efficiently.
We look to the future with confidence, knowing that we have a solid operational and financial foundation from which to build and support NextGen Healthcare’s continued leadership in the market.
The company’s board of directors added:
We thank Sheldon Razin for his many contributions and dedication to NextGen Healthcare since its founding almost 50 years ago. Sheldon is the major shareholder of the company. He will always be recognized as Founder and Chairman Emeritus of NextGen Healthcare.
With the director appointments announced today, NextGen Healthcare’s board of directors consists of eight independent directors and the new CEO of the company. Five of the nine directors are new to the board in the past four years and advance the board’s diversity in terms of race, gender, age and tenure. Collectively, the directors of the board bring decades of highly relevant experience across vendors, health insurance, life sciences and enterprise software to drive strategic execution and performance and growth of first order.
At the meeting, shareholders also approved the proposal for an exclusive forum for intra-company claims, the proposal to select the forum for securities claims and the adoption of proxy access. At the meeting, the shareholders did not approve the advisory proposal on executive compensation, the proposal to increase the threshold required for shareholders to call an extraordinary meeting from 10% to 15%, the proposal to board to fill only vacancies on the board and the proposal to give the board exclusive power to set the size of the board.
The Company will file the voting results for all proposals on a Form 8-K with the Securities and Exchange Commission within four business days.
About NextGen Healthcare, Inc.
NextGen Healthcare, Inc. (Nasdaq: NXGN) is a leading provider of outpatient-focused technology solutions. We empower the transformation of ambulatory care by partnering with medical, behavioral and dental providers on their journey to value-based care to improve health care for all. We go beyond DSE and PM. Our integrated solutions help increase clinical productivity, enrich the patient experience and ensure healthy financial results. We believe in better. Learn more about nextgen.com, and follow us on Facebook, Twitter, LinkedIn, Youtube and Instagram.
This communication may contain forward-looking statements within the meaning of federal securities laws, including, but not limited to, statements regarding future events, including, but not limited to the COVID-19 pandemic. , developments in the health sector and the regulatory framework, the future of the Company. performance, as well as management’s expectations, beliefs, intentions, plans, estimates or projections regarding the future (including, without limitation, statements regarding sales, net income and earnings per share ). There are risks and uncertainties that could cause results to differ materially from those stated in these forward-looking statements. Factors that could cause expected results to differ from those described in forward-looking statements and additional risks and uncertainties are set out in Part I, Section A of our most recent annual report on Form 10-K and filed by the continued in quarterly reports on Form 10-Q, including, but not limited to: volatility and uncertainty in the global economy, financial markets and our customers in light of the COVID-19 pandemic ongoing, including (i) potential slowdown or termination of preventive and elective medical procedures, (ii) delay in contracting for additional products and services by our customers, and (iii) delay in the sales cycle for new customers; a determination by the jury that the Company is responsible in a dispute brought forward by a former director and shareholder; the volume and timing of system sales and installations; the length of sales cycles and the installation process; the possibility that the products will not achieve or maintain market acceptance; seasonal sales trends and customer buying behavior; the impact of incentive payments under the American Recovery and Reinvestment Act on sales and the Company’s ability to meet ongoing certification requirements; uncertainties related to the future impact of US tax reform; the impact of investigations by government and regulatory agencies; the development by competitors of new or superior technologies; the timing, cost and success or failure of new product and service launches, product development and upgrades; errors or bugs not detected in the software; product liability; changing economic, political or regulatory influences in the health care industry; changes in product pricing policies; availability of third-party products and components; competitive pressures, including product offerings, pricing and promotional activities; the Company’s ability or inability to attract and retain qualified personnel; the impact of any proxy contests at the 2021 annual meeting of shareholders; possible regulation of the Company’s software by the United States Food and Drug Administration; changes in accounting estimates and assumptions used in preparing the financial statements for previous periods; disruptions caused by acquisitions of businesses, products or technologies; the extent to which the COVID-19 pandemic and the actions taken in response to it could adversely affect our financial condition and results of operations; and general economic conditions. A significant portion of the Company’s quarterly software and hardware product license sales are made in the last month of a fiscal quarter, typically with a concentration of such revenue earned in the last ten business days of that month. As a result of these and other factors, the revenues and results of operations of the Company are very difficult to predict. A large portion of the costs and expenses of the Company, such as personnel and facilities, are of a fixed nature and, therefore, a shortfall or decrease in quarterly and / or annual revenues generally results in lower profitability or losses. Therefore, the comparison of the financial performance of the Company from one period to another is not necessarily meaningful and should not be taken as an indicator of future performance. These forward-looking statements speak only as of the date hereof. The Company assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.